Effects of hesperidin in orange juice on blood and pulse pressures in mildly hypertensive individuals: a randomized controlled trial (Citrus study).

Montse Giralt, Rosa Solà, Lluís Arola, Josep M Del Bas, Antoni Caimari, Francesc Puiggrós, Núria Canela, Jordi Mayneris-Perxachs, Laura Rubió, Marta Romeu, Rosa M Valls, Yolanda Ortega, Francisco Martín-Luján, Ana Moragas, Judit Companys, Laura Pla-Pagà, Elisabet Llauradó, Lorena Calderón-Pérez, Anna Pedret

Journal: European journal of nutrition 2021;60(3):1277-1288

PMID: 32661681

Abstract

PURPOSE

To assess the sustained and acute effects, as well as the influence of sustained consumption on the acute effects, of orange juice (OJ) with a natural hesperidin content and hesperidin-enriched OJ (EOJ) on blood (BP) and pulse (PP) pressures in pre- and stage-1 hypertensive individuals.

METHODS

In a randomized, parallel, double-blind, placebo-controlled trial, participants (n = 159) received 500 mL/day of control drink, OJ, or EOJ for 12 weeks. Two dose-response studies were performed at baseline and after 12 weeks.

RESULTS

A single EOJ dose (500 mL) reduced systolic BP (SBP) and PP, with greater changes after sustained treatment where a decrease in diastolic BP (DBP) also occurred (P < 0.05). SBP and PP decreased in a dose-dependent manner relative to the hesperidin content of the beverages throughout the 12 weeks (P < 0.05). OJ and EOJ decreased homocysteine levels at 12 weeks versus the control drink (P < 0.05). After 12 weeks of EOJ consumption, four genes related to hypertension (PTX3, NLRP3, NPSR1 and NAMPT) were differentially expressed in peripheral blood mononuclear cells (P < 0.05).

CONCLUSION

Hesperidin in OJ reduces SBP and PP after sustained consumption, and after a single dose, the chronic consumption of EOJ enhances its postprandial effect. Decreases in systemic and transcriptomic biomarkers were concomitant with BP and PP changes. EOJ could be a useful co-adjuvant tool for BP and PP management in pre- and stage-1 hypertensive individuals.

Address: Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain.; Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av. de La Universitat, 1, 43204, Reus, Spain.; Functional Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Universitat Rovira i Virgili, Facultat de Medicina i Ciències de La Salut, Reus, Spain. [email protected].; Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Av. de La Universitat, 1, 43204, Reus, Spain. [email protected].; Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.; Institut Universitari d'Investigació en Atenció Primària-IDIAP Jordi Gol, Tarragona, Spain.; Primary Care Centre Jaume I, Institut Català de la Salut, Tarragona, Spain.; Primary Care Centre El Morell, Institut Català de la Salut, Tarragona, Spain.; Primary Care Centre Salou, Institut Català de la Salut, Tarragona, Spain.; Food Technology Department, XaRTA-TPV, Agrotecnio Center, Escola Tècnica Superior d'Enginyeria Agrària, University of Lleida, Av/ Alcalde Rovira Roure 191, 25198, Lleida, Spain.; Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences, Reus, Spain.; Departament de Bioquímica i Biotecnologia, Grup de Recerca en Nutrigenòmica, Universitat Rovira i Virgili, Tarragona, Spain.; Hospital Universitari Sant Joan de Reus, Reus, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.